Journals / Türk Oftalmoloji Dergisi / 2007 / Cilt: 37 - Sayı: 2

Interferon alpha treatment for idiopathic posterior uveitis with retinal vascular and optic disc involvement

Retina vasküler ve optik disk tutulumlu idyopatik arka üveit olgularında interferon Alfa-2a tedavisi

Pages
156–161
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It has been concluded with these results that interferon alpha-2a therapy may be an alternative treatment for idiopathic posterior uveitis with optic disc and retina vascular system involvement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Investigation of effectivity of interferon alpha-2a therapy on idiopathic posterior uve­itis with retina vascular and optic disc involvement.
📊
Key Findings & Data:Material and method: We have retrospectively studied the results of interferon alpha-2a treatment in posterior uveitic 43 patients with optic disc and retina vascular system involvement at the Ophthalmology Clinics in Gulhane Military Medical Faculty between the years of 1998-2004.
💡
Conclusion & Impact:Conclusion: It has been concluded with these results that interferon alpha-2a therapy may be an alternative treatment for idiopathic posterior uveitis with optic disc and retina vascular system involvement.
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Investigation of effectivity of interferon alpha-2a therapy on idiopathic posterior uve­itis with retina vascular and optic disc involvement. Material and method: We have retrospectively studied the results of interferon alpha-2a treatment in posterior uveitic 43 patients with optic disc and retina vascular system involvement at the Ophthalmology Clinics in Gulhane Military Medical Faculty between the years of 1998-2004. Only the cases resistant to conventional immunosuppressive therapy (cyclosporine, azot-hioprin) and/or cases who were treated with prednizolon treatment of lmg/kg dose and unsuc-cesful under the dose of 30 mg were included in the study.Results: Mean follow up time was 23.21±7.59 months. The recurrence rate was 0.63±0.44 yearly, in this period. At the end of the treatment, mean visual acuity of patients has increased 0.42±0.15 snellen line. At the end of the treatment, 65% of patients were in complete remission and 25% in partial remission. Flu-like syndrom, erythema and arhralgia were mostly seen side effects. Conclusion: It has been concluded with these results that interferon alpha-2a therapy may be an alternative treatment for idiopathic posterior uveitis with optic disc and retina vascular system involvement.

Özet

Amaç: Etyolojisi belirlenemeyen, optik sinir ve retina vasküler sistemini tutan arka üveit olgularında interferon alfa-2a tedavisinin etkinliğini araştırmak. Gereç ve Yöntem: Gülhane Askeri Tıp Fakültesi Göz Hastalıkları Kliniğinde 1998-2004 yılları arasında retina vasküler ve optik disk tutulumu gösteren arka üveit tanısı konulan ve in­terferon alfa-2a ile tedavi edilmiş olan 43 hasta retrospektif olarak çalışma kapsamına alındı. Çalışmaya konvansiyonel immünosupresif ilaçlara (siklosporin A, azothiyoprin) rağmen rekür-renslerle seyreden ya da en az lmg/kg prednizolon alıp doz 30 mg'ın altına düşürüldüğünde hastalığın alevlendiği hastalar dahil edilmiştir. Bulgular: Ortalama takip süresi 23.21 ± 7.59 ay idi. Bu süre içerisinde yılda ortalama 0.63 ± 0.44 rekürrens görüldü. Görme keskinliği seviyesi tedavi sonucunda ortalama 0.42 ±0.15 sıra artış gösterdi. Tedavi sonrasında hastaların %65'inde tam remisyon, %25'nde ise kısmi remis-yon saptandı. En sık görülen yan etkiler grip benzeri sendrom, enjeksiyon yerinde kızarıklık ve artralji idi. Sonuç: Bu sonuçlarla interferon alfa-2a tedavisinin bu grup hastalarda alternatif bir tedavi yöntemi oluşturabileceği kanaatine varıldı.

🔖

Cite This Article

SALİH, A., ERDEM, Ü., BAYRAKTAR, M. Z., DURUKAN, A. H., GÜNDOĞAN, F. Ç. (2022). Interferon alpha treatment for idiopathic posterior uveitis with retinal vascular and optic disc involvement. Türk Oftalmoloji Dergisi, Cilt: 37 - Sayı: 2, 156–161. https://ajindex.com/articles/638695

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Posterior Uveitis. In: Opremcak EM, Cunningham ET, Foster CS, Forster D, Moorthy RS, Lopatynsky M, eds. Intraocular Inflammation and Uveitis. American Aca­ demy of Ophthalmology 2003-2004,
  2. San Francisco Nussenblatt RB, Whitcup SM, Paletsine AG: Uveitis, fundamentals and clinical practice Mosby Co.St. louis 1996,334-351
  3. Young C, Lehner T, Barnes- CG. CD4 and CD8 cell res­ ponses to herpes simplex virus in Behcet's disease. Clin Exp Immunol 1988;73:6-10
  4. Lehner T, Fortune F, Studd M: T cell immunomodulation in Behcet's disease and consideration of microbial etio­ logy involving herpes simplex virus, heat shock proteins and streptococcal antigens. In: O'Duffy JD, Kokmen E, eds. Behcet's disease. New York: arcel Dekker, 1995:463- 73 Kotter I, Eckstein AK, Stubiger N, Zierhut M: Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Opthalmol. 1998. 82. 488-94
  5. Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Go erz G, Tsambaos D: Efficacy and safety of systemic re combinant interferon-alpha in Behcet's disease. J.İntern Med. 1998. 243. 367-72
  6. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Va­ lesini: Interferon alpha for ocular Behcet's disease. Acta Opthalmol Scand. 1997; 75:720-722
  7. Zouboulis CC, Orfanos CE: Treatment of Adamantiades- Behcet disease with systemic interferon alfa. Arch Der matol. 1998; 134:1010-1016
  8. O'Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman D, Jorizzo J, Weyand C, Matteson E: Interferon-alpha tre- atment of Behcet's disease. J Rheumatol. 1998; 25: 1938-1944
  9. Azizlerli G, Sarica R, Köse A, Ovul C, Kavala M, Kaya bali M, Erkan F, Kural Z: Interferon alfa-2a in the treat­ ment of Behcet's disease. Dermatology. 1996; 192: 239- 241 Caspi RR, Sun B, Agarwal RK, Silver PB, Rizzo LV, Chan CC, Wiggert B, Wilder RL: T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye. 1997; 11:209-212
  10. Durusoy C, Alpsoy E, Yilmaz E: Pityriasis rosea in a pa­ tient with Behcet's disease treated with interferon alpha 2A. J Dermatol. 1999; 26: 225-228
  11. Sanchez RJ, Pulido AMC, Castillo PMJ, Ocana MC, To ral PA, Lopez Checa F, Wichmann I: The use of interfe­ ron alpha-2a in the treatment of autoimmune uveitis Rev. Clin. Esp. 1996; 196: 293-298 Sanders MD: Duke-Elder lecture. Retinal arteritis, retinal vasculitis and autoimmune retinal vasculitis. Eye. 1987; 1:441-465 Hamza M, ed: The long-term treatment with interferon- alfa2a in Behcet's disease.